Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Ardelyx Inc (ARDX)

Ardelyx Inc (ARDX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,552,414
  • Shares Outstanding, K 245,247
  • Annual Sales, $ 407,320 K
  • Annual Income, $ -61,600 K
  • EBIT $ -41 M
  • EBITDA $ -38 M
  • 60-Month Beta 0.66
  • Price/Sales 3.81
  • Price/Cash Flow N/A
  • Price/Book 9.21

Options Overview Details

View History
  • Implied Volatility 64.09% (-9.60%)
  • Historical Volatility 49.33%
  • IV Percentile 22%
  • IV Rank 17.32%
  • IV High 151.31% on 02/06/26
  • IV Low 45.81% on 08/21/25
  • Expected Move (DTE 2) 0.43 (6.72%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 63
  • Volume Avg (30-Day) 797
  • Put/Call OI Ratio 0.29
  • Today's Open Interest 51,759
  • Open Int (30-Day) 51,961
  • Expected Range 5.90 to 6.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.12
  • Number of Estimates 6
  • High Estimate $-0.09
  • Low Estimate $-0.16
  • Prior Year $-0.17
  • Growth Rate Est. (year over year) +29.41%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.11 +24.68%
on 03/24/26
6.51 -2.15%
on 04/14/26
+0.58 (+10.12%)
since 03/13/26
3-Month
5.11 +24.68%
on 03/24/26
8.40 -24.23%
on 01/23/26
-0.68 (-9.59%)
since 01/15/26
52-Week
3.21 +98.29%
on 05/15/25
8.40 -24.23%
on 01/23/26
+1.72 (+37.18%)
since 04/15/25

Most Recent Stories

More News
Rajani Dinavahi, MD, Appointed Chief Medical Officer of Ardelyx

WALTHAM, Mass., April 01, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant...

ARDX : 6.28 (-0.79%)
Ardelyx Announces Recipients of the 2026 Derek Forfang Patient Advocate Award

WALTHAM, Mass., March 12, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a commercial-stage biopharmaceutical company focused on the development and commercialization of innovative medicines...

ARDX : 6.28 (-0.79%)
Ardelyx Announces Publication of a Review Article Demonstrating Rapid and Meaningful Symptom Relief with Tenapanor in IBS-C

WALTHAM, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant...

ARDX : 6.28 (-0.79%)
Ardelyx to Participate in Upcoming Investor Conferences

WALTHAM, Mass., March 04, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company focused on the development and commercialization of innovative medicines that meet significant...

ARDX : 6.28 (-0.79%)
Ardelyx and the LPGA Announce Multi-Year Partnership to Break Stigma Around Digestive Health Issues Impacting Millions

DAYTONA BEACH, Fla. and WALTHAM, Mass., Feb. 24, 2026 (GLOBE NEWSWIRE) -- The Ladies Professional Golf Association (LPGA) and Ardelyx (Nasdaq: ARDX), a biopharmaceutical company with a vision of creating...

ARDX : 6.28 (-0.79%)
Ardelyx: Q4 Earnings Snapshot

Ardelyx: Q4 Earnings Snapshot

ARDX : 6.28 (-0.79%)
Ardelyx Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

IBSRELA revenue grew 73% in 2025 to $274.2 million and total revenues reached $407.3 million Patient-first XPHOZAH strategy preserved access and drove growth in total dispenses Development programs...

ARDX : 6.28 (-0.79%)
Ardelyx to Report Full Year and Fourth Quarter 2025 Financial Results on February 19, 2026

WALTHAM, Mass., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines...

ARDX : 6.28 (-0.79%)
Ardelyx Receives New Patent for Tenapanor

WALTHAM, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines...

ARDX : 6.28 (-0.79%)
First Patient Dosed in ACCEL: Phase 3 Chronic Idiopathic Constipation Study of IBSRELA

WALTHAM, Mass., Jan. 28, 2026 (GLOBE NEWSWIRE) -- Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines...

ARDX : 6.28 (-0.79%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Ardelyx, Inc. is a clinical-stage biopharmaceutical company. It discovers, develops and commercializes small molecule therapeutics that work in the gastrointestinal tract to treat cardio-renal, GI and metabolic diseases. The Company's lead product candidate is Tenapanor which is in three ongoing Phase...

See More

Key Turning Points

3rd Resistance Point 6.74
2nd Resistance Point 6.62
1st Resistance Point 6.48
Last Price 6.28
1st Support Level 6.21
2nd Support Level 6.09
3rd Support Level 5.95

See More

52-Week High 8.40
Fibonacci 61.8% 6.42
Last Price 6.28
Fibonacci 50% 5.80
Fibonacci 38.2% 5.19
52-Week Low 3.21

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.